Related to U.S. Lead in Nanotechnology Depends on Growth of FDA and Gov’t Initiatives

• Republican Candidates Vouch for Agency Spending Cuts and hESC Restrictions
  While details differ, Romney, Gingrich, Santorum, and Paul all want to slice FDA and NIH’s budget.
  
• Care for Chimpanzees Retired from Research Use and Deciding Endangered Classification Key to Policy Changes
  NIH expects to give out about half as many grants for research using chimps once it implements restrictions.
  
• Latest Guideline Summary Document Solidifies EMA as Front Runner in Biosimilar Regulation
  Agency sought to answer various procedural questions that could come up during presubmission meetings.
  
• Reports Acknowledge FDA Progress but Cite Concerns on Agency Priorities, Management
  A major area of concern is the lower number of drugs that get the go-ahead after first review.
  
• FDA Reform Legislation Emerges as Exception to Washington Gridlock
  Bill includes reauthorization of PDUFA, which adds fees for generic and biosimilar developers.
  
• As Politicos Posture, Advocates Assess the Impact of Sequestration on Federal Agencies
  NIH estimates a 7.8% cut, while FASEB projects that number could go as high as 11.1%.
  
• EC Eyes Summer Overhaul for Clinical Trial Rules to Improve Drug Development
  Commission is moving from a directive to a regulation so guidelines will be implemented into law immediately across members.
  
• R&D Changes Foreseen After Supreme Court Obamacare Decision
  Innovative drugs that offer clear superiority over existing products likely among beneficiaries of overhaul.
  
• Potholes Threaten Medical Marijuana Progress
  Regulatory and political climate in U.S. right now doesn’t favor increasing patient access.
  
• Top 20 Pharma-Friendly Congress Members
  Who accepted the biggest pharmaceutical company contributions? Find out here.
  
• Candidates’ Science Answers Raise More Questions
  Presidental candidates’ responses to ScienceDebate.org query are inadequate and more discussion is essential.
  
• Weighing the Costs of GMO Labeling
  Whether genetically modified products need to be so named is on the ballot in California.
  
• Cost, Liability Fears Sink GMO Labeling
  Industry prevails in $46 million campaign against California’s Proposition 37, contending compliance would cost consumers up to $400 a year.
  
• Drug Companies Exert Greater Influence on Development
  Government funding, once the norm, is declining and pharma firms are in the driver’s seat.
  
• Building a Self-Destructive Mosquito
  Genetically modified mosquitos could be a way to curb the spread of dengue fever in Florida.
  
• SBIR Thinks Smaller
  New rules taking effect on January 28 aim to draw investor-owned smaller biopharmas to the federal grant program and STTR, its companion.
  
• No Passage to India
  Private investment dearth clouds the future of the subcontinent’s fast-growing biopharma industry.
  
• Arrivederci, GINA
  New rules on protecting genetic privacy are under way, as study rekindles debate over sharing vs. protecting data.
  
• Literature Review: ELISA—Detected Through A Quick Glance
  Researchers provide an assay chemistry that allows for a direct visual scoring of an ELISA result to detect protein analytes at ultralow concentrations.
  
• DNA Collection v. DNA Privacy
  Supreme Court weighs constitutionality of taking samples from arrested suspects absent a conviction.